Diabetic Nephropathy Market Report (2022 to 2030) – AstraZeneca … – GlobeNewswire

January 06, 2023 07:53 ET | Source: Growth Plus Reports Growth Plus Reports
Udaipur, INDIA
Pune, Jan. 06, 2023 (GLOBE NEWSWIRE) — According to a new market research report titled, “Diabetic Nephropathy Market by Drug Class (Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors, Mineralocorticoid Receptor Antagonists, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Outlook & Forecast 2022-2030″ published by Growth Plus Reports, the Diabetic Nephropathy Market is expected to grow at a CAGR of 4.3% from 2021 to reach US$ 3.25 billion by 2030.
Download PDF Brochure of Diabetic Nephropathy Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at:
https://growthplusreports.com/inquiry/request-sample/diabetic-nephropathy-market/8047
Growth Drivers
The increasing prevalence of diabetes is contributing to the growth of the global diabetes nephropathy market growth. Diabetic neuropathy is estimated to affect 6% to 51% of diabetic adults, depending on the type of diabetes, age, duration of diabetes, and glucose control. According to the International Diabetes Federation in 2021, nearly 537 million adults are living with diabetes globally and 1 out of 10 people have diabetes. The number is expected to reach around 643 million by 2030 and eventually, by 2045 it will reach nearly 783 million. Globally, around 6.7 million people are died because of diabetes in 2021, and almost $966 billion are spend on diabetes management. 
The global diabetic nephropathy market has been analyzed from three different perspectives – Drug Class, Distribution Channel, and Region
Excerpts from ‘by Drug Class’
The global diabetic nephropathy market based on drug class has been segmented into:
Angiotensin-converting enzyme (ACE) inhibitors are dominating the global diabetic nephropathy market due to their high therapeutic effect, and high ability to halt the development of diabetic nephropathy in diabetics with poorly managed hyperglycemia. Furthermore, ACE inhibitors delay the onset and slow the progression of diabetic nephropathy, which is expected to increase its adoption and thereby drive the growth of the segment in the global diabetic nephropathy market.
Excerpts From ‘by Distribution Channel’
The global diabetic nephropathy market based on the distribution channel has been segmented into:
The hospital pharmacies segment dominates the global diabetic nephropathy market owing increase in patient footfall in hospitals for diagnostic and treatment and the availability of emergency care facilities along with skilled medical staff. Additionally, the complications and serious issues caused by type 2 diabetes are also fueling the growth of hospital pharmacies diabetic nephropathy market growth.
Excerpts from ‘by Region Segmentation
The global diabetic nephropathy market has been segmented into:
The global diabetic nephropathy market is dominated by North America, followed by Asia Pacific. The region’s large share can be attributed to rising diabetes prevalence combined with a growing geriatric population and increased awareness of diabetic nephropathy. Additionally, increasing healthcare expenditure and developed infrastructure are also contributing to the growth of the North America diabetic nephropathy market.
Excerpts from ‘Competitive Landscape’
The prominent players operating in the global diabetic nephropathy market are:
Browse Detailed Summary of Research Report with TOC:
https://growthplusreports.com/report/diabetic-nephropathy-market/8047
Table of Content
Scope of the Report:
VALUE PROPOSITIONS RELATED TO THE REPORT:
CUSTOMIZATION OPTIONS:
Directly Purchase Premium Copy of Diabetic Nephropathy Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=LFcSh34lY9C0Ah32drsOLiPx3xqY6VnKwOnJnas8&report_id=8047&license=Single
About Us        
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

source